Adam C ElNaggar
Overview
Explore the profile of Adam C ElNaggar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Gunderson Jackson C, et al.
Gynecol Oncol
. 2023 Mar;
172:82-91.
PMID: 37001446
Purpose: Dickkopf-1 (DKK1) is a Wnt signaling modulator promoting tumor growth, metastasis, angiogenesis, and immunosuppression by regulating innate immunity. DKK1 is over-expressed in gynecologic cancers and is associated with shortened...
12.
Glaser G, Lara O, Pothuri B, Grimaldi C, Prescott L, Mastroyannis S, et al.
Gynecol Oncol
. 2022 Sep;
167(2):146-151.
PMID: 36154761
Objectives: Patients with gynecologic malignancies may have varied responses to COVID-19 infection. We aimed to describe clinical courses, treatment changes, and short-term clinical outcomes for gynecologic oncology patients with concurrent...
13.
Hou J, Chapman J, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, et al.
Gynecol Oncol
. 2022 Sep;
167(2):334-341.
PMID: 36117009
Objective: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. We examined the utility of circulating tumor DNA (ctDNA) as a prognostic biomarker for EOC by assessing its relationship...
14.
Cadoo K, Simpkins F, Mathews C, Liu Y, Provencher D, McCormick C, et al.
Gynecol Oncol
. 2022 Jul;
166(3):425-431.
PMID: 35803835
Objective: Olaparib treatment resulted in significant improvement in objective response rates (ORRs) and progression-free survival (PFS) over non‑platinum chemotherapy in patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) and...
15.
Wilhite A, Baca Y, Xiu J, Paladugu R, ElNaggar A, Brown J, et al.
Gynecol Oncol
. 2022 Apr;
166(1):108-116.
PMID: 35490034
Objectives: Disparate outcomes exist between Black and White patients with endometrial cancer (EC). One contributing factor is the disproportionately low representation of Black patients in clinical trials and in tumor...
16.
Simmons D, Blank S, ElNaggar A, Chastek B, Bunner S, McLaurin K
Adv Ther
. 2022 Apr;
39(6):2544-2561.
PMID: 35362863
Introduction: Ovarian cancer (OC) is one of the leading causes of cancer mortality among women in the United States. With the approval of first-line maintenance therapies, patients with OC experienced...
17.
Zhang N, Wilson B, Enty M, Ketch P, Ulm M, ElNaggar A, et al.
J Robot Surg
. 2021 Jul;
16(3):543-548.
PMID: 34236587
To assess the safety of same-day discharge (SDD) following robotic-assisted endometrial cancer staging and identify risk factors for postoperative admission in a diverse population. A review of patients who underwent...
18.
Ulm M, Redfern T, Wilson B, Ponnusamy S, Asemota S, Blackburn P, et al.
J Pers Med
. 2020 Dec;
10(4).
PMID: 33256002
Objective: The objective of this study is to identify and validate novel therapeutic target(s) in ovarian cancer. Background: Development of targeted therapeutics in ovarian cancer has been limited by molecular...
19.
Oaknin A, Friedman C, Roman L, DSouza A, Brana I, Bidard F, et al.
Gynecol Oncol
. 2020 Jul;
159(1):150-156.
PMID: 32723675
Objective: Somatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple...
20.
Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A, et al.
J Natl Compr Canc Netw
. 2019 Aug;
17(8):896-909.
PMID: 31390583
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge...